1. Background {#sec44477}
=============

New onset atrial fibrillation (AF) is the most common arrhythmia following coronary artery bypass grafting (CABG) surgery ([@A4584R1]). Reported incidence of AF after CABG surgery varies from 25% to 40% occurring usually between second and fourth postoperative days ([@A4584R2]-[@A4584R6]). Although this arrhythmia is self-limiting in most cases, it can cause hemodynamic disturbances, increased medical costs, and prolonged hospitalization ([@A4584R7]-[@A4584R10]). Short-term effects of postoperative AF (POAF) are well known but its long-term consequences are not well established or clearly understood. Most of the data related to the effects of POAF on long-term mortality and morbidity rates are limited to first five years after surgery; few studies have reported very late effects of post-CABG AF ([@A4584R11]-[@A4584R13]).

2. Objectives {#sec44478}
=============

The objective of this study was to evaluate the impact of POAF on very late (\> 5 years) mortality and morbidity rates after isolated CABG.

3. Patients and Methods {#sec44481}
=======================

3.1. Study Protocol and Patient Population {#sec44479}
------------------------------------------

In this retrospective cohort study, we reviewed our database of Adult Cardiac Surgery to identify patients who underwent isolated CABG between October 2004 and October 2006 and had more than five years follow-up. Patients with history of preoperative AF, permanent pacemaker or implantable cardioverter-defibrillator implantations, and thyroid diseases were excluded from the study.

Our database contained detailed information on patient demographics, preoperative risk factors, operation details, postoperative hospital course, and morbidity and mortality outcomes. These data consisted of gender, age, height, and weight of patients as well as history of hypertension, diabetes, dyslipidemia, smoking, hypothyroidism, and asthma. We also evaluated the patients for other arrhythmic disorders, percutaneous coronary intervention, cardiovascular disease, angiography data, left ventricular dysfunction, ventricular hypertrophy, and reports of bypass surgery. Survival was measured as time (in day) to either death or last follow up. A written informed consent was obtained from all participants and the local Ethics Committee approved the study protocol.

Post-CABG AF was defined according to established criteria of STS ([@A4584R12]). It was our general practice to restore sinus rhythm in most patients within 24-48 hours after the onset of POAF using antiarrhythmic drugs (AADs) or by employing electrical cardioversion. If medical therapy resulted in reestablishment of sinus rhythm or control of ventricular rate and the patient was asymptomatic, the medication continued for 6 weeks. In persistent AF with unsuccessful rhythm cardioversion, warfarin was also administrated and patients were discharged on warfarin (in the absence of any contraindication) and referred to cardioversion 4 to 6 weeks later. In the absence of AF recurrence, antiarrhythmic drugs were discontinued. Causes of death were recognized by a review of hospital records, death certificates, and autopsy reports. All patients were visited in six months intervals. The incomplete data were followed up by telephone contact. At each visit, patients were monitored for symptom changes, myocardial infarction, heart failure, embolic cerebrovascular accident, pulmonary emboli, cardiac interventions, medications, and cardiac rhythm (AF episodes).

3.2. Statistical Analysis {#sec44480}
-------------------------

The data were recorded in SPSS 17 for windows (SPSS Inc. Chicago, IL, USA). Continuous variables are presented as mean ± SD. The Student's t-test was employed to compare data between the two groups with a normal distribution. Otherwise, a non-parametric Mann-Whitney U test was employed. To statistically evaluate isolated effects of POAF on mortality rate, a multivariate Cox proportional hazard model was constructed for related survival time as a function of POAF, adjusted for 13 covariates. Adjusted hazard ratios (HRs) along with 95% confidence intervals (CI) were computed for POAF and 13 covariates. Additionally, Kaplan-Meier product-limit estimates were generated to provide in time survival estimates at post-operative points. Provided estimates for POAF status were compared for equality using log-rank tests. A P value \< 0.05 was considered statistically significant.

4. Results {#sec44483}
==========

4.1. Patient Characteristics {#sec44482}
----------------------------

Study population consisted of 989 post-CABG patients with more than 5-year follow-up. The mean age at the time of cardiac surgery was 60 ± 10 years from which 87% were men. Hypertension was manifested in 50%, dyslipidemia in 45%, and diabetes in 31% of patients, and 32% were smokers. Mean ejection fraction was 44 ± 8.0% in the study population. Overall incidence of AF in whole study population was 15.8% (n = 156).

4.2. Baseline Characteristics of the Patients With and Without Postoperative Atrial Fibrillation {#sec47086}
------------------------------------------------------------------------------------------------

Demographic and clinical characteristics of the study population by AF status were summarized in [Table 1](#tbl11744){ref-type="table"}. Patients with POAF were older than patients without POAF (65 ± 7.0 vs. 59 ± 11.0, P = 0.001) and presented with more severe symptoms (expressed as NYHA functional class) (2.4 ± 0.9 vs. 2.1 ± 0.7, P = 0.001). The prevalence of comorbidities including hypertension (67% vs. 47%, P = 0.001), hyperlipidemia (50% vs. 39%, P = 0.009), renal failure (15% vs. 2.0%, P = 0.001), peripheral vascular disease (19% vs. 4.0, P = 0.001), and chronic obstructive lung disease (8.0% vs. 4.0%, P = 0.05) were also significantly higher in patients with POAF. However, the prevalence of smoking and diabetes were similar in both groups. Left ventricular function was significantly lower in patients with POAF (43.0 ± 8.0% vs. 46.0 ± 7.0%, P = 0.001). Left atrial dimension was also significantly greater in POAF group (37 ± 9.0 vs. 35 ± 5.0 mm respectively, P = 0.001). Patients without POAF were medicated more than POAF patients by beta-blockers (80% vs. 64%, P = 0.001), angiotensin converting enzyme inhibitors (69% vs. 58%, P = 0.004), and statins (61% vs. 48%, P = 0.002).

###### Demographic and clinical characteristics by postoperative atrial fibrillation

                                                        POAF ^[a](#fn7871){ref-type="table-fn"}^ (n = 156)   No POAF (n = 833)   *P* value
  ----------------------------------------------------- ---------------------------------------------------- ------------------- -----------
  Age, year                                             65 ± 7.0                                             59 ± 11.0           0.001
  Male                                                  129 (83 %)                                           731 (87 %)          0.085
  LVEF^[a](#fn7871){ref-type="table-fn"}^               43.0 ± 8.0                                           46.0 ± 7.0          0.001
  LA^[a](#fn7871){ref-type="table-fn"}^ dimension, mm   37 ± 9.0                                             35 ± 5.0            0.001
  Hypertension                                          105 (67 %)                                           391 (47 %)          0.001
  Hyperlipidemia                                        78 (50 %)                                            323 (39 %)          0.009
  Smoking                                               51 (33 %)                                            289 (35 %)          0.630
  Diabetes                                              54 (35 %)                                            255 (31 %)          0.300
  Renal failure                                         24 (15 %)                                            17 (2.0 %)          0.001
  Peripheral vascular disease                           30 (19 %)                                            34 (4.0 %)          0.001
  Myocardial infarction                                 57 (36 %)                                            357 (43 %)          0.140
  Obstructive lung disease                              12 (8.0 %)                                           34 (4.0 %)          0.050
  Percutaneous revascularization                        12 (8.0 %)                                           136 (16.0 %)        0.006
  Preoperative drugs                                                                                                             
  Betablockers                                          99 (64 %)                                            663 (80 %)          0.001
  ACE ^[a](#fn7871){ref-type="table-fn"}^ inhibitors    90 (58 %)                                            578 (69 %)          0.004
  Calcium blockers                                      45 (29 %)                                            272 (33 %)          0.350
  Statins                                               75 (48 %)                                            510 (61 %)          0.002

^a^ Abbreviations: ACE: Angiotensin-Converting Enzyme ; LVEF=Left Ventricular Ejection Fraction; LA: Left Atrium; POAF: Postoperative Atrial Fibrillation

Considering intraoperative factors, intra-aortic balloon pump (IABP) was more inserted in POAF patients compared to patients without POAF (1.9% vs. 0%, P = 0.004). Patients with POAF experienced more stroke during surgery than those in other group (5.8% vs. 0%, P = 0.001). Evaluation of discharge medications showed that patients with POAF were more likely to be discharged on beta-blocker, calcium channel blocker, warfarin, and amiodarone ([Table 2](#tbl11745){ref-type="table"}).

###### Discharge medications according to postoperative atrial fibrillation

                                                       POAF ^[a](#fn7872){ref-type="table-fn"}^ (n = 156 )   No POAF (n = 833 )   *P* value
  ---------------------------------------------------- ----------------------------------------------------- -------------------- -----------
  Beta-blockers                                        156 (100 %)                                           782 (94 %)           0.001
  Calcium Chanel- blocker                              30 (19 %)                                             85 (10 %)            0.001
  ACE ^[a](#fn7872){ref-type="table-fn"}^ inhibitors   132 (85 %)                                            697 (84 %)           0.769
  Statin                                               108 (71 %)                                            680 (82 %)           0.002
  Warfarin                                             36 (23 %)                                             34 (4.0 %)           0.001
  Aspirin                                              150 (96 %)                                            799 (96 %)           0.89
  Amiodarone                                           51 (33 %)                                             34 (4.0 %)           0.001

^a^ Abbreviations: ACE: Angiotensin-Converting Enzyme; POAF: Postoperative Atrial Fibrillation

4.3. Association between New Onset POAF and Long-Term Mortality and Morbidity {#sec47087}
-----------------------------------------------------------------------------

Long-term mortality rate was 2.3% in whole population (5.8% in group with POAF vs. 1.7% in group without POAF). New onset POAF was associated with higher long-term mortality (HR = 3.6; 95% CI: 1.52-8.43; P = 0.005). In patients with POAF, myocardial infarction (55%, n = 5), cerebrovascular accident (33%, n = 3), and congestive heart failure (12%, n = 1) were diagnosed as etiologies of the death.

We determined morbidity as incidence of one complication during the follow up; thereby the incidence of long-term morbidity was 12.5% (25% in group with POAF vs. 10% in group without POAF). Postoperative late outcome were summarized in [Table 3](#tbl11746){ref-type="table"}. The frequency of postoperative complications, such as stroke (HR = 7.5, 95% CI: 3.84-14.52, P = 0.001) and myocardial infarction (HR = 6.66, 95% CI: 5.74-7.73, P = 0.001) were higher in patients with POAF compared to those without POAF. Patients with POAF remained hospitalized longer than patients without POAF (15 days vs. 11 days, P = 0.001). Long-term morbidity was also higher in POAF patients than that of in the second group (HR = 2.9; 95%CI: 1.91-4.49, P = 0.001). In multivariable analysis, atrial fibrillation remained as an independent predictor of very late mortality. Other predictors included history of HTN and myocardial infarction ([Table 4](#tbl11747){ref-type="table"}). Multivariate analysis in presence of other confounding factors or other covariate affecting morbidity also showed that POAF is an independent predictor of long-term morbidity. Other predictors for morbidity were NYHA classification, smoking status, renal failure, and history of myocardial infarction ([Table 5](#tbl11748){ref-type="table"}).

###### Postoperative complications by presence of atrial Fibrillation

                                 POAF ^[a](#fn7873){ref-type="table-fn"}^ (n = 156)   No POAF (n = 833)   *P* value
  ------------------------------ ---------------------------------------------------- ------------------- -----------
  Heart failure                  9 (6.0 %)                                            34 (4.0 %)          0.343
  Postoperative stroke           21 (13.0 %)                                          17 (2.0 %)          0.001
  Myocardial infarction          9 (6.0 %)                                            0 (0.0 %)           0.001
  Renal failure                  3 (2.0 %)                                            34 (4.0 %)          0.192
  Length of hospital stay, day   15 ± 2.5                                             11 ± 4.0            0.001

^a^ Abbreviation: POAF: Postoperative Atrial Fibrillation

###### Predictors of mortality after coronary artery bypass surgery in multivariate analysis

  Variable                         Adjusted Hazard Ratio (95% CI^[a](#fn7874){ref-type="table-fn"}^)   *P* value
  -------------------------------- ------------------------------------------------------------------- -----------
  Atrial fibrillation              3.3 (0.04-10.8)                                                     0.040
  Female gender                    1.2 (0.11-13.0)                                                     0.870
  Age                              0.94 (0.88-1.00)                                                    0.050
  classification                   0.98 (0.57-1.67)                                                    0.950
  Smoking status                   1.74 (0.52-5.86)                                                    0.360
  Diabetic mellitus                0.49 (0.13-1.72)                                                    0.260
  Renal failure                    0.78 (0.08-7.52)                                                    0.830
  Peripheral vascular disease      1.18 (0.16-8.27)                                                    0.860
  Myocardial infarction            35 (4.35-277.0)                                                     0.001
  Percutaneous revascularization   2.5 (0.47-12.70)                                                    0.280
  Hypertension                     3.7 (1.25-11.40)                                                    0.010
  Hyperlipidemia                   1.58 (0.54-4.65)                                                    0.400

^a^ Confidence Interval

###### Predictor of morbidity after coronary artery bypass surgery in multivariate analysis

  Variable                                   Adjusted Hazard Ratio(95% CI ^[a](#fn7875){ref-type="table-fn"}^)   P value
  ------------------------------------------ ------------------------------------------------------------------- ---------
  AF                                         4.0 (2.35-6.96)                                                     0.001
  Female gender                              1.0 (1.41-2.80)                                                     0.880
  Age                                        1.0 (0.98-1.03)                                                     0.370
  NYHA ^[b](#fn7876){ref-type="table-fn"}^   1.4 (1.07-1.81)                                                     0.010
  Hypertension                               1.0 (0.64-1.53)                                                     0.990
  Hyperlipidemia                             6.8 (0.66-12.65)                                                    0.001
  Smoking status                             3.5 (2.19-5.69)                                                     0.001
  Diabetic mellitus                          1.5 (0.89-2.67)                                                     0.110
  Renal failure                              4.8 (1.27-18.01)                                                    0.020
  Peripheral vascular disease                0.6 (0.20-1.70)                                                     0.330
  Myocardial infarction                      1.9 (1.19-2.95)                                                     0.006
  Percutaneous revascularization             0.5 (0.18-1.13)                                                     0.090

^a^ Confidence Interval

^b^ **Abbreviation: NYHA: New York Heart Association**

5. Discussion {#sec44487}
=============

5.1. Major Findings {#sec44484}
-------------------

The present study clearly demonstrated that new onset POAF increases very late mortality after isolated CABG and is associated with relevant thromboembolic sequel. The incidence of POAF (15.8%) was consistent with which reported earlier in literature.

5.2. Postoperative Atrial Fibrillation and Long-Term Mortality and Morbidity {#sec44485}
----------------------------------------------------------------------------

Few studies have evaluated the effect of POAF on long-term survival after CABG. In a study of 6475 patients, Villareal et al. ([@A4584R4]) reported a higher risk of late mortality in patients with POAF after isolated CABG (OR, 3.4; 95%CI 1.6-7.5). However, age was entered as a dichotomous variable in their multivariate model which could have biased the effect of age on mortality rate. Mariscalco et al.([@A4584R11]) similarly reported an increased risk of long-term mortality in patients with POAF (HR = 2.99; 95% CI: 2.33-3.84). Results of this study were also confounded by 8% patient loss during follow-up and inclusion of patients with preoperative paroxysmal or persistent AF. Filardo et al.([@A4584R12])reported similar findings from 6899 isolated CABG patients. A significantly lower ten-year survival was observed in patients who developed POAF compared to those without POAF (HR = 1.29; 95% CI: 1.16-1.45). We similarly confirmed negative survival effect of POAF in CABG patients. In the present study, POAF increased the risk of death by 3.6 in CABG patients.

The frequency rates of postoperative complications such as ischemic stroke, myocardial infarction, and prolonged hospital stay were increased in patients with POAF. In the present study, the risk of ischemic stroke were increased by 7.5 times in patients with POAF . The increased risk of cerebrovascular accident occurred despite the fact that AF patients were adequately managed by oral anticoagulants. Higher risk of the stroke in AF patients may be explained by impaired hemodynamics associated with reduced ventricular filling and circulatory stasis in the left atrium that rendered patients susceptible to stroke and other embolic events. This complication also adversely affected patient's survival because stroke was responsible for at least one-third of late mortalities. In addition, the increased morbidity related to the stroke always associated with increased length of hospital stay. Although we did not measure the exact role of ischemic stroke in prolongation of hospital stay, this complication may have importantly contributed to longer hospital stay observed in AF group (15 days vs. 11 days, P \< 0.001).

Another important finding of this study was that POAF is an age-independent risk factor for postoperative MI with an adjusted hazard ratio of 6.6 (95% CI: 5.74-7.73). This complication had marked effect on poor outcome and mortality of patients as late deaths secondary to MI were frequent in this study (55%). A similarly increased risk of MI in POAF patients has been demonstrated in two previous studies. In the study of Ahlsson and associates, a higher rate of death due to MI was reported (6.7% vs. 3.0%, P = 0.041) ([@A4584R13]). Mariscalco and colleagues similarly reported an increased risk of death due to embolic events (MI and stroke) in CABG patients with POAF (HR, 4.33; 95%CI 1.78--10.52, P = 0.001) ([@A4584R11]). Currently, there is no clear explanation for increased cardiovascular mortality due to embolic events in patients with POAF. Is it related to occurrence of late AF? Currently, there are some data showing that patients experienced POAF are more prone to develop AF during follow-up ([@A4584R13]). An episode of POAF was the strongest independent risk factor for development of late AF with an adjusted risk ratio of 8.31 (95%CI, 4.20-16.43). Another hypothesis for higher rate of late mortality in POAF patients might be related to the fact that, POAF is associated with an increased incidence of several comorbidities including advanced age, heart failure, renal failure, chronic lung disease, and peripheral vascular disease.

5.3. Study Limitations {#sec44486}
----------------------

Prevalence of postoperative AF was 15.8%, which is significantly lower than other reports. This low prevalence may be explained by exclusion of patients with valvular disease and those with history of the preoperative AF. In this cohort study of patients who underwent CABG, the prevalence of POAF after CABG was 15.8% in our population and was associated with increased mortality and morbidity rates even more than five years after surgery. Further researches may focus on development of more effective methods for prevention as well as identification of high risk patients who are susceptible to new onset POAF and thereby better prophylactic plans could be designed for such patients.
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**Implication for health policy/practice/research/medical education:**Further research should focus on the development of more effective prevention and also identification of the high risk patients for new onset POAF so that a better prophylaxis can be targeted for these patients.
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